Fasudil (HA-1077) HCl: Selective ROCK Inhibitor—Mechanisms & Evidence

Executive Summary: Fasudil (HA-1077) HCl is a potent, selective inhibitor of Rho-associated protein kinase (ROCK), with an IC₅₀ of 0.74 μM under standard assay conditions (product_spec). Its inhibition of ROCK-I and ROCK-II reduces cancer cell proliferation and migration and induces apoptosis, without affecting upstream RhoA GTPase activity (internal_article). Fasudil’s efficacy is demonstrated in both in vitro and in vivo models, including murine myeloproliferative disorders (product_spec). The compound is supplied as a solid, soluble in DMSO, ethanol, and water, with recommended storage at -20°C (product_spec). This article clarifies boundaries and misconceptions, contrasts prior guides, and presents protocol-ready parameters for research use.

Biological Rationale

ROCK is a serine/threonine kinase within the AGC family and a pivotal effector in the Rho/ROCK pathway. It coordinates actin cytoskeleton dynamics, cell shape, motility, proliferation, and apoptosis. Dysregulation of ROCK signaling is implicated in cancer progression, fibrotic diseases, and some hematologic disorders (internal_article). Targeting ROCK with selective inhibitors like Fasudil (HA-1077) HCl enables researchers to explore pathway-specific effects on cell fate, migration, and survival mechanisms, supporting both basic and translational research.

Mechanism of Action of Fasudil (HA-1077) HCl

Fasudil (HA-1077) HCl competitively inhibits ATP binding to ROCK-I and ROCK-II, with an IC₅₀ of 0.74 μM (product_spec). Unlike non-selective kinase inhibitors, Fasudil maintains selectivity within the AGC kinase family, sparing upstream RhoA activity. The drug’s inhibition of ROCK leads to decreased phosphorylation of downstream targets (e.g., myosin light chain), suppressing actomyosin contractility and cell motility. This cascade results in reduced cancer cell proliferation, migration, and increased apoptosis, as observed in bladder (5637, UM-UC-3) and oral cancer (SCC-4) lines in a dose-dependent manner (product_spec). By comparison, Fasudil exhibits a distinct chemical scaffold from other ROCK inhibitors such as Y-27632, supporting use in differential pathway studies (internal_article—this article details unique structural and solubility features, whereas the current dossier emphasizes in vivo translational relevance).

Evidence & Benchmarks

• Fasudil (HA-1077) HCl inhibits ROCK-I and ROCK-II with an IC₅₀ of 0.74 μM under standard kinase assay conditions (source: product_spec).
• In human bladder cancer cell lines (5637, UM-UC-3), Fasudil reduces proliferation and migration, and induces apoptosis in a dose-dependent manner (source: product_spec).
• Oral administration at 100 mg/kg daily in a Cbl/Cbl-b deficiency-driven murine myeloproliferative disorder model significantly reduces total white cell and monocyte counts, with a trend toward prolonged survival (source: product_spec).
• Fasudil does not impair upstream RhoA activation, isolating ROCK-specific effects (source: internal_article—this article extends prior work by focusing on selectivity data).
• The Rho/ROCK pathway, distinct from the Hippo pathway, is validated as a driver of abnormal proliferation and migration in several disease models, though direct crosstalk with Hippo is an emerging research area (source: original_paper).

Applications, Limits & Misconceptions

Fasudil (HA-1077) HCl is widely used for:

• Probing Rho/ROCK pathway inhibition in cancer biology and disease models.
• Elucidating mechanisms of cell proliferation inhibition, migration suppression, and apoptosis induction in vitro and in vivo.
• Studying hematological disorders using validated murine models.
• Exploring pathway crosstalk, especially in synergy or contrast with Hippo or other signaling axes (internal_article—this discussion uniquely connects Rho/ROCK with Hippo signaling, whereas the present article provides quantitative boundaries and selectivity data).

Common Pitfalls or Misconceptions

• Fasudil is not a pan-kinase inhibitor; its selectivity profile must be confirmed for each new cell or tissue context (source: internal_article).
• Upstream RhoA activity is not suppressed—interpretation of total Rho/ROCK pathway inhibition should be avoided unless verified (source: internal_article).
• In vivo efficacy and dosing are model-dependent; pharmacokinetic and toxicity data must be established for each animal system (workflow_recommendation).
• Fasudil hydrochloride should not be used for long-term solution storage at room temperature due to potential hydrolysis (source: product_spec).
• Direct translation from animal to human use is unsupported; all results are for research only (workflow_recommendation).

Workflow Integration & Parameters

Protocol Parameters

• in vitro kinase inhibition | IC₅₀ = 0.74 μM | ROCK-I/II activity assays | Validates selective inhibition of ROCK | product_spec
• cancer cell viability/proliferation | 1–20 μM | 5637, UM-UC-3, SCC-4 cell lines | Dose-response for proliferation, migration, and apoptosis | product_spec
• in vivo administration | 100 mg/kg, oral, daily | Cbl/Cbl-b-deficient murine model | Reduces leukocyte/monocyte counts in myeloproliferative disease | product_spec
• stock solution preparation | ≥16.4 mg/mL in DMSO | General lab use | Ensures accurate dosing and solubility | product_spec
• storage | -20°C (solid/solution) | All applications | Preserves compound integrity | product_spec
• workflow recommendation: Always validate cell line-specific sensitivity and confirm pathway engagement via biochemical readouts before endpoint analysis | N/A | General research | Maximizes specificity and reproducibility | workflow_recommendation

For advanced workflows and troubleshooting, see the APExBIO Fasudil (HA-1077) HCl (A5734) product page.

Conclusion & Outlook

Fasudil (HA-1077) HCl remains a benchmark tool for selective, potent ROCK inhibition in research settings. Its efficacy in modulating cell proliferation, migration, and apoptosis in validated cancer and hematological models is well established (product_spec). Current evidence supports its use for dissecting Rho/ROCK pathway mechanics, while boundaries in model specificity and translational application must be respected. Emerging studies underscore the complexity of pathway crosstalk, such as with Hippo signaling, but further research is needed to clarify these interactions (original_paper). For detailed protocols and advanced troubleshooting, consult internal guides such as this workflow guide (which details experimental reproducibility strategies), or this strategic review (which contextualizes Fasudil in translational pipelines).